Physician profile
Salah Uddin
NPI 1861676736
$976.44
in general payments reported to CMS, 2019-2025
13 companies · $252 in 2025
The $252 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.77 · 2022: $59.81 · 2023: $151 · 2024: $489 · 2025: $252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $860 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $859.59 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $282.70 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $127.96 | 2022-2024 | Farxiga, Lokelma |
| Merck Sharp & Dohme LLC | $120.81 | 2023-2025 | Prevymis, Zerbaxa, Dificid |
| Calliditas Therapeutics US INC. | $77.35 | 2022-2025 | Tarpeyo |
| Veloxis Pharmaceuticals, INC. | $71.87 | 2023-2024 | Envarsus |
| Vifor Pharma, INC. | $69.57 | 2019-2023 | Veltassa |
| Novo Nordisk INC | $51.28 | 2025 | Ozempic |
| Otsuka America Pharmaceutical, INC. | $50.36 | 2024-2025 | Jynarque |
| Cormedix INC. | $31.05 | 2024 | Defencath |
| Ardelyx, INC. | $28.88 | 2024 | Ibsrela |
| Kyowa Kirin, INC. | $26.77 | 2023 | Crysvita |
| Fresenius USA Marketing, INC. | $19.81 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.03 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salah Uddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.